ERBB2 and breast carcinoma: Strikingly, neratinib reversed the efficacy of CDK4/6 inhibitor and endocrine therapy by reducing HER2 mRNA stability in HR+/HER2-low breast cancer through the interaction of HER2 3’-UTR region with hsa-miR-23a-5p.